A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan - The CLEAR Taiwan Study
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms CLEAR Taiwan
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
Most Recent Events
- 28 Jul 2025 Planned End Date changed from 31 Dec 2025 to 30 Nov 2025.
- 28 Jul 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Oct 2025.
- 28 Jul 2025 Status changed from not yet recruiting to recruiting.